OBJECTIVE: To explore the relationship between gasdermin D (GSDMD) and gastric cancer (GC) cell proliferation, and to determine whether the downregulated expression of GSDMD contributed to the tumorigenesis and proliferation of GC cells.
INTRODUCTION
Gastric cancer (GC) is the fourth most common cancer in man and the fifth most common cancer in women worldwide, with a high mortality. 1, 2 It is a multifactorial disorder that results from abnormal activation of several oncogenic signaling pathways, the activation of oncogenes, the inactivation of tumor suppressor genes and the dysregulation of cell cycle-related proteins. 3 However, the molecular mechanism underlying GC remains unclear.
Programmed cell death, a genetically controlled process that regulates the regeneration and differentiation of gastric epithelial cells, is important for understanding the carcinogenesis of GC. 4, 5 As a newly found programmed cell death agent, pyroptosis is involved in various diseases, but few studies have been published regarding the relationship between pyroptosis and GC. [6] [7] [8] Recent studies have focused on the gasdermin D (GSDMD) protein, which acts as the trigger of pyroptosis to maintain cell homeostasis. [9] [10] [11] The collapse of this suicide process in the gastric epithelium is considered the cause of GC cell proliferation.
Previous studies have shown that in upper gastrointestinal (GI) cancers the expression and function of four gasdermin (GSDM) family genes differed from each other. 12 The GSDM family has been found to participate in the apoptotic signaling to suppress the development of GC. 13 Furthermore, inflammasomes, functioning in the upstream of GSDMD, have been found to be associated with various cancers and play important roles at each stage of cancer development. 7, 14 However, its potential role and mechanisms in GC are still unclear.
In this study we aimed to explore the relationship between GSDMD and GC cell proliferation, to investigate whether the downregulated expression of GSDMD contributed to the tumorigenesis and proliferation of GC by activating the extracellular signalregulated kinase 1/2 (ERK1/2), signal transducer and activator of transcription 3 (STAT3) and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling and regulating cell cycle-related proteins, thus to provide a new perspective for the pathogenesis of GC and its treatment strategies.
MATERIALS AND METHODS
Surgically resected GC tissues and adjacent noncancerous tissues GC tissues and matched adjacent non-cancerous tissues (>5 cm from the lesion) were obtained from 61 patients who underwent surgical resection at the Xijing Hospital, Air Force Military Medical University (Xi'an, Shaanxi Province, China). None of the patients had received radiochemotherapy before the surgery. Altogether 6 paired tissues were used for protein extraction and 39 paired tissues for RNA extraction. All the 61 paired tissues were embedded with paraffin for microarray analysis. Written informed consent was obtained from each patient. And the protocol was approved by the Ethics Committee of Xijing Hospital.
Cell culture
Five gastric cancer cell lines (MKN-28, MKN-45, SGC7901, BGC823 and AGS) and a normal human gastric epithelial cell line were cultured in the Dulbecco's Modified Eagle Medium (high glucose; Life Technologies, Gaithersburg, MD, USA) supplemented with 10% fetal bovine solution (FBS; Biological Industries, Kibbutz Beit-Haemek, Israel), 100 U/mL penicillin and 100 μg/mL streptomycin in a humidified incubator at 37 C with 5% carbon dioxide. 15 Lentiviral infection and short interfering RNA (siRNA) transfection GSDMD-overexpressed lentivirus and empty vector lentivirus were purchased from GeneChem (Shanghai, China). The BGC823 cells (2 × 10
5
) were infected with 1 × 10 6 transducing units of GSDMDoverexpressed lentivirus (BGC823/GSDMD) or empty vector lentivirus (BGC823/vector) in the presence of 10 μg/mL polybrene (Genechem). The culture medium was changed to normal medium 12 h after infection. Seventy-two hours after lentiviral infection, BGC823/GSDMD and BGC823/vector cells were selected with puromycin (Thermo Fisher Scientific, Waltham, MA, USA) at a final concentration of 2 μg/ mL for more than one week. To silence the expression of GSDMD in SGC7901 cells, 2 μg doublestranded siRNA-targeting human GSDMD (purchased from Biomics Biotechnologies Co., Ltd, Nantong, Jiangsu Province, China), 1 mL Opti-MEM (Invitrogen, Karlsruhe, Germany) media and 5 μL HiPerFect ® Transfection Reagent (Qiagen, Dusseldorf, Germany) were mixed and incubated according to the manufacturer's instructions. The knockdown and overexpression efficiency of GSDMD were further analyzed by Western blot and quantitative real-time polymerase chain reaction (qRT-PCR).
Cell viability analysis
The growing BGC823/GSDMD and BGC823/vector cells were harvested and seeded in the 96-well plates (1 × 10 4 cells/well) and were then incubated at 37 C overnight to allow the cell adhesion. According to the manufacturer's instructions, the number of viable cells was assessed using the Cell Counting Kit-8 (CCK-8) assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). Cell viability was evaluated by measuring the average optical density (OD) at 450 nm using the Varioskan Flash Multimode Reader (Thermo Fisher Scientific) in each group. The experiments were performed in triplicate.
Cell proliferation analysis
After silencing the expression of GSDMD, SGC7901 cells were plated at equal number at 2 × 10 5 /well in a 96-well plate. Cell proliferation was analyzed using bromodeoxyuridine (BrdU) Cell Proliferation Assay Kit (Merck Millipore, Darmstadt, Germany) according to the manufacturer's instructions. Varioskan Flash Multimode Reader (Thermo Fisher Scientific) was used to measure the absorbance of the sample at 450 nm.
Colony formation analysis
Log-phase BGC823/GSDMD and BGC823/vector cells were harvested and separately placed in the 6-well plates (1 × 10 3 cells/well) and were then cultured in an incubator. After 2 weeks the cells were washed thrice with ice-cold Dulbecco's phosphatebuffered saline (PBS; Gibco, Carlsbad, CA, USA), fixed in 5 mL of 4% paraformaldehyde for 15 min, and stained with gentian violet (Beyotime Institute of Biotechnology, Shanghai, China). Visible colonies were counted manually.
Xenografted tumors in nude mice
Nude mice (5-6 weeks old) were obtained from the Experimental Animal Center of the Fourth Military Medical University (Xi'an, Shaanxi Province, China). All the experimental protocols were approved by the Committee on Animal Experimentation of Institutional Animal Care and were conducted under the Ethical Standards of the Fourth Military Medical University. All the mice had free access to standard chew and water. The BGC823/GSDMD and BGC823/vector cells were digested and re-suspended in PBS. Then 2 × 10 6 cells in 0.1 mL PBS solution were injected subcutaneously into the left upper back of the mice. One month after inoculation, all the mice were sacrificed under deep anesthesia, and the tumors were isolated and weighed. The tumor size was measured by calipers, and the tumor volumes were calculated using the following formula: tumor volume (mm 
Cell cycle analysis
The BGC823/GSDMD and BGC823/vector cells were synchronized in the G 0 /G 1 phase by 24-h serum starvation and the cell cycle was restarted by incubation in 10% FBS at 0 h, 3 h, 6 h, 9 h, 12 h and 15 h. Harvested cells at the given time points were washed with 10 mL of ice-cold PBS, fixed in 70% cold ethanol (-20 C) , and stored at -20 C until analysis. After overnight fixation, the cells were washed with icecold PBS and stained with propidium iodide (Leagene, Beijing, China). Using a flow cytometer (EPICS XL; Beckman Coulter, Inc., Miami, FL, USA), DNA content of the stained nucleus of each sample was analyzed. The cell cycle stages of each sample were analyzed using MultiCycle Software (Beckman Coulter, Inc.). The proliferative index (PI) was calculated as follows: PI = (S + G 2 )/(S + G 2 + G 1 ). 16 
qRT-PCR
Total RNA was extracted from 39 paired GC tissues and adjacent non-cancerous tissues using the MiniB-EST Universal RNA Extraction Kit (TaKaRa, Tokyo, Japan). Concentration and purity of isolated RNA were measured with an ultraviolet spectrophotometer at 260 nm and 280 nm. The ratio of OD260/OD280 of 1.8-2.0 indicates a relatively high RNA purity for subsequent analysis. Complementary DNA (cDNA) was synthesized by reverse transcription using the PrimeScript RT Master Mix (Perfect Real Time) (TaKaRa, Tokyo, Japan) according to the manufacturer's instructions. The expression of Gsdmd mRNA was analyzed by Real Time Fluorescent Quantitative PCR Instrument with CFX Manager Software 3.0 (Bio-Rad, CA, USA) according to the manufacturer's instructions. The reaction conditions were as follows: initial denaturation at 95 C for 30 s, followed by 45 cycles of denaturation at 95 C for 5 s and annealing at 60 C for 30 s. Melt curve was then detected. The mRNA relative expressions were normalized to β-actin.
Western blot analysis
The protein of cells (after washed with ice-cold PBS thrice) and 6 pairs of patient tissues (GC and adjacent non-cancerous tissues) were collected in the RIPA lysis buffer (Beyotime Institute of Biotechnology) containing protease inhibitor cocktail and phosphatase protease inhibitor cocktail (both from Calbiochem, San Diego, CA, USA). The concentration of total protein was determined by Coomassie Brilliant Blue staining (Beyotime Institute of Biotechnology). The total proteins were separated using 10% sodium dodecyl sulfate-polycrylamide gel electrophoresis (SDS-PAGE), and then transferred onto a polyvinylidene difluoride (PVDF) membrane (Merck Millipore). After blocked with 10% skim milk and 0.1% TBS Tween-20 buffer for 1 h, the membranes were incubated with the primary monoclonal antibody at 4 C overnight, and were incubated with corresponding secondary antibodies at room temperature for 2 h on the next day. The primary monoclonal antibodies included GSDMD (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), CDK-2 (1:1000; Merck Millipore), Cyclin A2 (1:1000; Abcam, Cambridge, MA, USA), PCNA, p-AKT, AKT, p-ERK, ERK, p38, p-p38, STAT, p-STAT (1:1000; Cell Signaling Technology, Danvers, MA, USA) and β-actin (1:5000; Sigma-Aldrich, St. Louis, MO, USA) and peroxidase-conjugated goat anti-rabbit/antimouse IgG antibody (Zhongshan Golden Bridge Biotechnology, Beijing, China) were used as the secondary antibodies. The immunoreactive bands were visualized by enhanced chemiluminescence (Merck Millipore, Darmstadt, Germany) using a ChemiDoc XRS Imaging system (Bio-Rad). All the experiments were repeated in triplicate.
Statistical analysis
Statistical analyses were performed by using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA) and SPSS 18.0 (IBM, Armonk, NY, USA). All the experiments were repeated at least thrice. Continuous variables were presented as mean AE standard error of mean (SEM). The comparison of the groups was performed using the Student's t-test or Chisquare test when appropriate. P value of less than 0.05 was considered to be statistically significant.
RESULTS

GSDMD expression was downregulated in both GC cell lines and mouse GC tissues
To investigate the involvement of GSDMD in GC, GSDMD levels in five GC cell lines and the immortal human gastric epithelial cell line were evaluated by Western blot and qRT-PCR. Decreased protein levels of GSDMD were confirmed by Western blot in the GC cells compared with the normal gastric epithelial cells (Fig. 1a,b) , indicating that the downregulation of GSDMD may contribute to the pathogenesis of GC. The Gsdmd mRNA levels were significantly downregulated in the GC cell lines compared with those in the normal gastric epithelial cells as well (Fig. 1c) .
To further verify the role of GSDMD in GC, GSDMD expression in both GC tissues and matched adjacent non-cancerous tissues was detected. Using Western blot and qRT-PCR analyses, both mRNA and protein expressions of GSDMD decreased in the cancerous tissues compared with the adjacent non-cancerous tissues (Fig. 1d,e) . Additionally, we analyzed the GSDMD levels by immunohistochemical stain in GC tissue microarrays, and the results further confirmed that the expression of GSDMD was significantly decreased in GC (Fig. 1f, Table 1 ).
Diminished expression of GSDMD promoted GC cell proliferation
To evaluate the functional significance of GSDMD in GC, BGC823 cell line was transfected with lentivirus to upregulate GSDMD expressions, and the increased expression of GSDMD was examined by qRT-PCR and Western blot (Fig. 2a,b) . Furthermore, the colony formation assay confirmed a reduced proliferation of GSDMD on BGC823 cells (Fig. 2c) . The CCK-8 assay demonstrated that the upregulated expression of GSDMD inhibited cell proliferation (Fig. 2d) .
Conversely, siRNA was used to silence the GSDMD expression in SGC7901 cells, and its decreased expression was confirmed by Western blot and qRT-PCR (Fig. 2e,f ) . Using the BrdU array, we drew a proliferation curve that used time as the horizontal coordinate and the average absorbance value of each group as the vertical axis (Fig. 2g) . As expected, silencing GSDMD cells significantly accelerated cell proliferation compared with the scrambled negative control.
To verify the pyroptosis-inducing activity of GSDMD in GC, we administered lipopolysaccharides (LPS) by electroporation to induce pyroptosis in GSDMDtransfected BGC823 (BGC823/GSDMD) and BGC823 (BGC823/vector) cells. We found that the BGC823/ GSDMD cells died extensively (Fig. 2h) . Next, plasmids-containing full-length GSDMD and the activated GSDMD-N terminus were transfected into BGC823 cells. We found that the cells with the transfected GSDMD-N terminus became swollen and the membranes ruptured (Fig. 2h) .
Low expression of GSDMD promoted tumor growth in nude mice
To confirm the effect of GSDMD in vivo, xenografted tumors in nude mice were used to evaluate tumorigenicity. We injected BGC823/GSDMD and BGC823/ vector cells into the left upper back of nude mice. One month after the injection the mice were sacrificed and the tumors were isolated completely, we found that much smaller tumors had formed in the mice injected with BGC823/GSDMD cells than in those injected with BGC823/vector cells (Fig. 2i, j) ,
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Gasdermin D and gastric cancer proliferation with a lower tumor weight in the BGC 823/GSDMD group (P < 0.05, Fig. 2k ). Additionally, tumor volumes in the BGC823/GSDMD group were significantly smaller than those in the BGC823/vector group (P < 0.01, Fig. 2l ).
GSDMD inhibited the S phase to G 2 /M phase transition in BGC823 cells
To explore the potential roles of GSDMD in inhibiting the cell proliferation of GC, we compared the cell cycles between BGC823/GSDMD and BGC823/vector cells by flow cytometry. By 24-h serum starvation, we synchronized all the cells in the G0 phase. Next, the cells were harvested, stained with propidium iodide and analyzed by flow cytometry. We found that the cell cycle was arrested in the S phase to G 2 /M phase in the BGC823/ GSDMD cells. These data suggested that GSDMD inhibited the S to G 2 /M transition in BGC823/GSDMD cells. Therefore, GSDMD might suppress cell proliferation by affecting the cell cycle (Fig. 3a,b) .
To confirm the effects of GSDMD in regulating cell cycle, we identified the molecules that contributed to the S/G 2 cell cycle transition, such as Cyclin A2 and CDK2. Western blot revealed that the expressions of Cyclin A2 and CDK2 were decreased after treated with GSDMD, indicating that GSDMD regulated the S/G 2 cell cycle transition in GC. Western blot of proliferating cell nuclear antigen (PCNA) and c-myc further confirmed that GSDMD protected against GC cell proliferation (Fig. 4) .
Abnormal inactivation of the oncogenic cell signaling pathway led to inappropriate hyperplasia. Several proliferation and survival-related signaling pathways were studied by Western blot. We found that the expressions of p-ERK1/2, p-STAT3 and p-AKT were significantly decreased in the BGC823/GSDMD group, indicating that GSDMD might regulate GC cell proliferation through the ERK1/2, STAT3 and PI3K/AKT signaling pathway (Fig. 4) .
DISCUSSION
In this study, we found that GSDMD protected against GC cell proliferation. Its expression was relatively lower in five GC cell lines than in normal gastric epithelial cell line. Similarly, the decreased expression of GSDMD was detected in the cancerous tissues of GC patients. Further experiments confirmed that GSDMD inhibited the S to G 2 phase transition in the cell cycle via CDK-2 and Cyclin A2. Additionally, the PI3K/AKT, STAT3 and ERK1/2 signaling pathways were found to participate in GSDMDregulated GC development.
A previous study has revealed that the gasdermin family suppresses GC as a target of LMO1 in transforming growth factor (TGF)-β-dependent apoptotic signaling pathway. 13 As a key molecule of pyroptosis, not apoptosis, GSDMD can be cleaved by inflammasomes to defend against external stimuli, yielding an N-terminal fragment of GSDMD that binds to lipids such as cardiolipin and phosphatidylethanolamine, ultimately leading to pore formation in membranes. 10, 17 Because the N-terminal fragment is the functional domain of GSDMD in pyroptosis, we transfected the BGC823 cells with the plasmids-containing GSDMD-N terminus, and found that the cells died with a typical pyroptotic morphology. The same phenomenon was observed when we used LPS with electroporation to induce pyroptosis in BGC823/GSDMD cells. Furthermore, the tumorigenesis of GC is frequently associated with chronic inflammation, and it has been well documented that chronic inflammation caused by Helicobacter pylori infection and chronic gastritis damage the normal gastric mucosal structure, modulate the host inflammatory response and eventually accelerate the development of GC. 7, [18] [19] [20] In response to those danger signals, the inflammasomes are activated and then regulate pyroptosis to promote cell suicide. 21, 22 However, the probable role and mechanism of GSDMD in GC remain unclear. In vitro, both the results of the CCK-8 assay and the colony formation assay suggest that forced GSDMD overexpression in BGC823 cells can reverse the cell proliferation of GC; in vivo, the tumor formation assay in nude mice confirmed this result. Because the reduced expression of GSDMD in SGC7901 cells is the lowest among all the five GC cells, we knocked down the expressions of GSDMD in SGC7901 by siRNA. The results of the BrdU array showed that silenced GSDMD accelerated cell proliferation.
In our experiment we found that the cell cycle was arrested in the S/G 2 /M phase in the BGC823/ GSDMD cells by flow cytometry. Cell cycle progression is regulated by the activation of Cyclin/CDK complexes, and several studies have shown that this complex plays a role in S phase progression. 23, 24 It participates in the process of DNA synthesis from the beginning to end and is involved in the S/G 2 transition. 25, 26 Therefore, we hypothesized in the BGC823/ GSDMD cells that the dysfunction or downregulated expression of Cyclin A2/CDK2 contributed to the S to G 2 /M arrest. As expected, Western blot confirmed that GSDMD decreased Cyclin A2 and CDK2 expressions in BGC823 cells. Taken together, the decreased expression of GSDMD may promote cell proliferation by modulating the transcription of Cyclin A2 and CDK2 to accelerate the cell cycle transition from the S to G 2 phase.
The ERK1/2, STAT3 and PI3K/AKT signaling pathways have been demonstrated to play important roles in tumor progression and cell survival. 27, 28 In this study, we showed that p-ERK1/2, p-STAT3 and p-AKT were decreased when GSDMD was upregulated in BGC823 cells. In other researches on pyroptosis, the cell signaling pathways were studied to explain the findings on GSDMD protein function. It has been suggested that the protective action of pyroptosis relies on the RISK pathway, which includes PI3K/AKT and ERK1/2 activation in cardioprotection. 29 However, mechanisms other than the activation of the ERK1/2, STAT3 and PI3K/AKT pathways and the regulation of cell cycle-related proteins may also exist and may be responsible for the carcinostasis function of GSDMD. In conclusion, this study strongly supported that GSDMD might protect against GC cell proliferation, at least partially, through the inactivation of the ERK, STAT3 and PI3K/AKT pathways, subsequently inhibiting the Cyclin A2/CDK-2 complex to arrest the S/G 2 phase transition. Although this report sheds new light on the link between GSDMD and GC cell proliferation, there is still much work to be done to investigate the function of GSDMD in mediating the malignant transformation and utilizing GSDMD as a diagnostic and treatment strategy of GC. 
